• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Corvention launches KardiaPSI balloon catheter in US with first cases

Corvention launches KardiaPSI balloon catheter in US with first cases

June 24, 2026 By Sean Whooley

Corvention KardiaPSI balloon catheter
The KardiaPSI balloon catheter [Image courtesy of Corvention]
Corvention announced today that it completed the first case in the U.S. with its proprietary KardiaPSI balloon catheter.

The procedure, performed by Dr. Alan Zajarias in St. Louis, marked the official start of a limited rollout for the balloon catheter. Flagstaff, Arizona-based Corvention won FDA clearance for the device in balloon aortic valvuloplasty (BAV) in May.

Corvention says KardiaPSI provides interventionalists with an ultra-high-pressure solution for the precise dilation of stenotic aortic valves. It designed KardiaPSI to address the mechanical challenges of calcified valve anatomy. The device delivers high-pressure dilation with controlled expansion and a short footprint for more predictability and accuracy during valvuloplasty procedures.

The company said its catheter features fiber-reinforced materials to maintain its profile and integrity under extreme pressures. Its precision sizing allows physicians to “dial up” treatment millimeter by millimeter. This optimizes anatomical fit while minimizing interaction with unwanted structures. The device also offers fast inflation and deflation using a single syringe/inflation device for procedural efficiency.

Corvention said a limited launch allows it to ensure strong clinical support, precise case execution and deep procedural collaboration with early adopting institutions.

Commentary from Corvention officials and doctors using KardiaPSI

Michael Franklin, CEO of Corvention, said:

“We are thrilled to achieve this pivotal milestone alongside Dr. Zajarias and his exceptional team in St. Louis. The successful clinical debut of the KardiaPSI balloon catheter underscores our commitment to providing interventionalists with advanced, high-performance tools designed to optimize outcomes in structural heart procedures. This first case lays the foundation for our controlled rollout across elite cardiovascular centers nationwide.”

Dr. Alan Zajarias said:

“Being the first center in the United States to utilize the KardiaPSI technology is a testament to our program’s dedication to clinical excellence and cutting-edge care. The device performed exactly as anticipated, remaining very stable in place, with fast inflation/deflation times, that are critical in these complex anatomical environments.”

Filed Under: Cardiovascular, Catheters, Structural Heart Tagged With: Corvention

More recent news

  • Teleflex wins Breakthrough Device designation for Freesolve resorbable scaffold
  • FDA clears Solventum’s combo wound care platform following Acera acquisition
  • GE HealthCare begins new global partnerships to advance theranostic imaging technology
  • Siemens Healthineers, Nvidia launch radiotherapy AI collaboration
  • J&J, Medtronic present pulsed field ablation data from global real-world use

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy